KS27: OUTCOMES OF AUTOLOGOUS CHONDROCYTE IMPLANTATION IN THE PATELLOFEMORAL JOINT

Abstract

Traditionally, the results of autologous chondrocyte implantation (ACI) in the patellofemoral joint have been considered inferior to those in the weightbearing femoral condyles. This study investigated the clinical effectiveness of patellofemoral ACI in a large, single-surgeon cohort.

This study reviewed prospectively collected data of patients treated with ACI for defects of the trochlea and/ or patella with a minimum follow-up of 2 years. Clinical outcomes were evaluated by SF-36; WOMAC, Knee Society Score, modified Cincinnati Score and a patient satisfaction survey.

130 patients reached a minimum follow-up of 2 years (2–9 years, average 56.5 months) after treatment involving the patellofemoral articulation. There were 77 men (59%) and 53 women (41%), the average age at the time of implantation was 37.5 years (15–57 years). The treatment groups included

1. isolated patella (n = 14);

2. isolated trochlea (n = 15);

3. patella plus trochlea (n = 5);

4. weight-bearing condyle plus patella (n = 19);

5. weightbearing condyle plus trochlea (n = 52);

6. weightbearing condyle plus patella plus trochlea (n = 25).

The average surface area of patellar and trochlear defects was 4.7 cm2 (n = 63) and 5.8 cm2 (n = 98), respectively. The average resurfacing per knee was 11 cm2. There were 16 failures (12%) that could be attributed to a patellar or trochlear defect. 80% of patients rated their outcome as good or excellent, 18% rated their outcome as fair, and 2% rated outcome as poor.

ACI of the patellofemoral articulation provided a Significant improvement in quality of life as measured by functional scores and patient satisfaction survey. The failure rate was comparable to ACI used in other locations, such as the weightbearing femoral condyles.